Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

CARdinal signs of variant ICANS

Juliane Gust, Nirali N. Shah

Blood (2024) 144 (13): 1352–1354.

https://doi.org/10.1182/blood.2024025664

Published: 2024

Journal Articles

How I treat post-immunotherapy relapsed B-ALL

Adam J. Lamble, Alexandra E Kovach, Nirali N Shah

Blood blood.2024024517.

https://doi.org/10.1182/blood.2024024517

Published: 2024

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood (2023) 142 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2023-185507

Published: 2023

Journal Articles

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Blood (2023) 142 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2023-180867

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Blood (2023) 142 (Supplement 1): 257.

https://doi.org/10.1182/blood-2023-177594

Published: 2023

Journal Articles

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Susan R Rheingold, Lingyun Ji, Lia Gore, Xinxin Xu, Deepa Bhojwani, Nirali N. Shah, Elizabeth A. Raetz, Mignon L. Loh, Maureen M. O'Brien

Blood (2023) 142 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2023-183103

Published: 2023

Journal Articles

Engineering Off-the-Shelf Gamma Delta CAR T Cells for the Treatment of Acute Myeloid Leukemia

Alka Dwivedi, Lynn Fu, Chris Daniel Chien, Marie Pouzolles, Nirali N. Shah, Naomi Taylor

Blood (2023) 142 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2023-190357

Published: 2023

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

Generation of Hinge-Modified Human CD19 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of CD19-Low Leukemia

Victoria M. Giordani, Justin Mirazee, Marie Pouzolles, Mehdi Benzaoui, Chris Daniel Chien, Saliha Majdoul, Sooraj Achar, Adam Kenet, Madison Wahlsten, Gregoire Altan-Bonnet, James N Kochenderfer, Nirali N. Shah, Taisuke Kondo, Naomi Taylor

Blood (2023) 142 (Supplement 1): 6819.

https://doi.org/10.1182/blood-2023-187954

Published: 2023

Journal Articles

How I treat refractory CRS and ICANS after CAR T-cell therapy

Michael D. Jain, Melody Smith, Nirali N. Shah

Blood (2023) 141 (20): 2430–2442.

https://doi.org/10.1182/blood.2022017414

Published: 2023

Journal Articles

How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL

Regina M. Myers, Nirali N. Shah, Michael A. Pulsipher

Blood (2023) 141 (11): 1251–1264.

https://doi.org/10.1182/blood.2022016937

Published: 2023

Journal Articles

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Blood (2022) 140 (Supplement 1): 4610–4611.

https://doi.org/10.1182/blood-2022-168928

Published: 2022

Journal Articles

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Blood (2022) 140 (Supplement 1): 10332–10334.

https://doi.org/10.1182/blood-2022-166082

Published: 2022

Journal Articles

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Adam J. Lamble, Yueh-Yun Chi, Bill H. Chang, Anupam Verma, Kelly E Faulk, Alexandra McLean Stevens, Lauren Pommert, Sarah Tucker, Benjamin Brookhart, Nirali N. Shah, Christopher L. Brooks, Tariq I. Mughal, Alan S. Wayne, Soheil Meshinchi, Todd M. Cooper

Blood (2022) 140 (Supplement 1): 6102–6103.

https://doi.org/10.1182/blood-2022-163503

Published: 2022

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel

Blood (2022) 140 (Supplement 1): 12973–12975.

https://doi.org/10.1182/blood-2022-165289

Published: 2022

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

CARdinal signs of variant ICANS

How I treat post-immunotherapy relapsed B-ALL

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Engineering Off-the-Shelf Gamma Delta CAR T Cells for the Treatment of Acute Myeloid Leukemia

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Generation of Hinge-Modified Human CD19 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of CD19-Low Leukemia

How I treat refractory CRS and ICANS after CAR T-cell therapy

How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only